Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
11.73 USD   +1.30%
11/22Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
BU
11/03IRONWOOD PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
11/03Transcript : Ironwood Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ironwood Pharmaceuticals Says Linzess Meets Primary, Secondary Endpoints in Phase 3 Trial in Pediatric Patients With Functional Constipation

09/06/2022 | 08:18am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.14% 159.62 Delayed Quote.17.89%
IRONWOOD PHARMACEUTICALS, INC. 1.30% 11.73 Delayed Quote.0.60%
SBM OFFSHORE N.V 0.00% 14.91 Real-time Quote.13.86%
All news about IRONWOOD PHARMACEUTICALS, INC.
11/22Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Con..
BU
11/03IRONWOOD PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
11/03Transcript : Ironwood Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 03, 2..
CI
11/03Ironwood Pharmaceuticals : 3Q 2022 Investor Update Conference Call
PU
11/03Ironwood : Q3 Earnings Snapshot
AQ
11/03GUIDANCE: (IRWD) IRONWOOD PHARMACEUTICALS Forecasts Fiscal Year 2022 Revenue Ra..
MT
11/03Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q3 Revenue $108.6M
MT
11/03Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q3 EPS $0.28
MT
11/03Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year..
BU
11/03Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
CI
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 423 M - -
Net income 2022 180 M - -
Net cash 2022 417 M - -
P/E ratio 2022 11,6x
Yield 2022 -
Capitalization 1 799 M 1 799 M -
EV / Sales 2022 3,26x
EV / Sales 2023 2,41x
Nbr of Employees 219
Free-Float 98,4%
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 11,73 $
Average target price 13,00 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Sravan Kumar Emany Chief Financial Officer & Senior Vice President
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Marcel Moulaison Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.0.60%1 799
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918